Skip to content

Psilocybin research published in 2016

Page 2 of 3: studies 21 to 40 of 41, newest first. Back to the psilocybin overview

Studies

Hallucinogen Use Disorders.

Child and Adolescent Psychiatric Clinics of North America July 2016 Rashad Hardaway, Jason Schweitzer, Joji Suzuki

Use of hallucinogenic substances as a public health concern has increased over the past decade. Among adolescents, there are increasing emergency department presentations for intoxication with these drugs, contrary to decreasing reported use of classical hallucinogens such as LSD. Academic and governmental groups have monitored use of hallucinogens, highlighting a notable change in perceptions...

ChemInform Abstract: Observations Concerning the Synthesis of Tryptamine Homologues and Branched Tryptamine Derivatives via the Borrowing Hydrogen Process: Synthesis of Psilocin, Bufotenin, and Serotonin.

ChemInform July 1, 2016 Silvia Bartolucci, Michele Mari, Giovanni Di Gregorio et al.

AbstractThe selective indole alkylation reaction applying the Ir‐catalyzed‐borrowing hydrogen methodology and using amino alcohols (II), (V), (VII) as suitable nitrogen‐containing electrophiles is reported.

MAGIC MUSHROOMS: from sacred entheogen to Class A drug

Entertainment and Sports Law Journal June 27, 2016 Charlotte Walsh 2 citations

On July 18th, section 21 of the Drugs Act 2005 came into force: as a result, magic mushrooms are now classified as a Class A drug under the Misuse of Drugs Act 1971. Following a brief look at magic mushrooms and their effects, this paper charts their usage throughout history, from Saharan tribes in ancient times, through the psychedelic revolution of the 1960s, to the boom in (recently halted)...

DOI: 10.16997/eslj.100 (opens in new tab) Magic telescope Boom Context archaeology Traditional medicine +1

Entwicklung des Missbrauchs psychotroper Pflanzen und Pilze in Deutschland – Interpretation der Zahlen aus 3 Giftinformationszentren für die Jahre 2007–2013

Das Gesundheitswesen June 14, 2016 Jörg Pietsch, K. Scheffel, Daniela Acquarone et al. 2 citations

AIM OF THE STUDY: Based on an abundance of information on the internet, psychotropic plants and mushrooms are of increasing relevance as legal and cheap alternatives to other illicit drugs. Due to the lack of a German database, the abuse of selected biogenic drugs using reported exposures to 3 German Poison Information Centres (PICs) was examined. METHODS: Information on abuse of biogenic drugs...

DOI: 10.1055/s-0042-108644 (opens in new tab) Psilocybin Tropane Drugs of abuse Hallucinogen

PM506. Psilocybin Clinical Trial: Acute Effects and its relationship to the brain activity as measured by quantitative EEG

The International Journal of Neuropsychopharmacology May 27, 2016 Filip Tylš, Michaela Viktorinová, Dominika Prokopcova et al. 10 citations

Objective: Schizophrenia patients have a higher prevalence of type 2 diabetes mellitus than the general population, and even first-episode, drug-naive (FEDN) patients with schizophrenia have shown a higher prevalence of impaired glucose tolerance (IGT) than the general population.We aimed to investigate the prevalence of abnormal glucose tolerance after glucose loading, and to examine the...

A Phenomenological Examination of Psilocybin and its Positive and Persisting Aftereffects

NeuroQuantology May 24, 2016 Joseph A. Zamaria 32 citations

This study is an examination of the positive and persisting psychological and behavioral aftereffects in eight individuals who reported consumption of psilocybin-containing mushrooms. Mushrooms containing psilocybin have been used for healing and spiritual purposes for thousands of years, and the therapeutic applications of psilocybin were scientifically examined beginning in the mid-20th...

DOI: 10.14704/nq.2016.14.2.943 (opens in new tab) Psilocybin Cognitive psychology Telepathy Hallucinogen +2

Sixty seconds on . . . psilocybin

BMJ May 18, 2016 Nigel Hawkes 5 citations

Not so fast. There’s a long way to go. But a study in London has shown that the active ingredient in magic mushrooms, psilocybin, may be effective against treatment resistant depression. Its effects were quick—within a week—and more than 40% of the patients treated were still in remission three months later.1 Yes, as far as it goes. These were people whose depression had …

DOI: 10.1136/bmj.i2775 (opens in new tab) Psilocybin Magic telescope Depression economics Psychoanalysis +3

Altered states: psilocybin for treatment-resistant depression

The Lancet Psychiatry May 17, 2016 Philip J. Cowen 13 citations

“Alice remained looking thoughtfully at the mushroom for a minute, trying to make out which were the two sides of it; and as it was perfectly round, she found this a very difficult question”. To resolve the issue, Alice ate the mushroom; in more recent times, however, experimentation with psilocybin-containing magic mushrooms has been strongly discouraged. In the UK, in 2005, magic mushrooms...

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.

The Lancet Psychiatry May 17, 2016 Robin Carhart-Harris, Mark Bolstridge, James Rucker et al. 1,546 citations

BACKGROUND: Psilocybin is a serotonin receptor agonist that occurs naturally in some mushroom species. Recent studies have assessed the therapeutic potential of psilocybin for various conditions, including end-of-life anxiety, obsessive-compulsive disorder, and smoking and alcohol dependence, with promising preliminary results. Here, we aimed to investigate the feasibility, safety, and efficacy...

DOI: 10.1016/s2215-0366(16)30065-7 (opens in new tab) Psilocybin Depression treatment Mental health research

Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA.

The Lancet Psychiatry April 5, 2016 Michael C Mithoefer, Charles S. Grob, Timothy D Brewerton 237 citations

4-phosphorloxy-N,N-dimethyltryptamine (psilocybin) and methylenedioxymethamfetamine (MDMA), best known for their illegal use as psychedelic drugs, are showing promise as therapeutics in a resurgence of clinical research during the past 10 years. Psilocybin is being tested for alcoholism, smoking cessation, and in patients with advanced cancer with anxiety. MDMA is showing encouraging results as...

Exploring Hallucinogen Pharmacology and Psychedelic Medicine with Zebrafish Models

Zebrafish March 22, 2016 Evan J. Kyzar, Allan V. Kalueff 29 citations

After decades of sociopolitical obstacles, the field of psychiatry is experiencing a revived interest in the use of hallucinogenic agents to treat brain disorders. Along with the use of ketamine for depression, recent pilot studies have highlighted the efficacy of classic serotonergic hallucinogens, such as lysergic acid diethylamide and psilocybin, in treating addiction, post-traumatic stress...

Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years

Therapeutic Advances in Psychopharmacology March 18, 2016 Rafael G. Dos Santos, Flávia de Lima Osório, José Alexandre S. Crippa et al. 306 citations

To date, pharmacological treatments for mood and anxiety disorders and for drug dependence show limited efficacy, leaving a large number of patients suffering severe and persistent symptoms. Preliminary studies in animals and humans suggest that ayahuasca, psilocybin and lysergic acid diethylamide (LSD) may have antidepressive, anxiolytic, and antiaddictive properties. Thus, we conducted a...

Ayahuasca: Pharmacology, neuroscience and therapeutic potential

Brain Research Bulletin March 11, 2016 Elisabet Domínguez‐clavé, Joaquim Soler, Matilde Elices et al. 220 citations

Ayahuasca is the Quechua name for a tea obtained from the vine Banisteriopsis caapi, and used for ritual purposes by the indigenous populations of the Amazon. The use of a variation of the tea that combines B. caapi with the leaves of the shrub Psychotria viridis has experienced unprecedented expansion worldwide for its psychotropic properties. This preparation contains the psychedelic 5-HT2A...

The “Endless Trip”: Psychopathology and psychopharmacology in the Hallucinogen Persisting Perception Disorder (HPPD)

European Psychiatry March 1, 2016 Laura Orsolini, Alessandro Valchera, Duccio Papanti et al. 3 citations

Introduction Hallucinogen Persisting Perception Disorder (HPPD) is a syndrome characterized by prolonged or reoccurring perceptual symptoms, reminiscent of acute hallucinogen effects. HPPD was associated with a broader range of LSD (lysergic acid diethylamide)-like substances, including cannabis, MDMA (methylenedioxymethamphetamine), psilocybin, mescaline and other psychostimulants....

Psychedelic and nonpsychedelic LSD and psilocybin for cluster headache

Canadian Medical Association Journal February 16, 2016 Wm. Jeptha Davenport 14 citations

Tupper and colleagues highlight reasons for renewed interest in the use of psychedelic drugs as adjuncts to psychotherapy.[1][1] Clinicians have an interest in extending research into headache medicine, especially the treatment of cluster headaches (prevalence roughly 0.1%) when episodes are

DOI: 10.1503/cmaj.1150082 (opens in new tab) Full text (opens in new tab) Psilocybin Cluster headache Headaches Alternative medicine +1

The paradoxical psychological effects of lysergic acid diethylamide (LSD)

Psychological Medicine February 5, 2016 Robin Carhart-Harris, Mendel Kaelen, Mark Bolstridge et al. 301 citations

Background Lysergic acid diethylamide (LSD) is a potent serotonergic hallucinogen or psychedelic that modulates consciousness in a marked and novel way. This study sought to examine the acute and mid-term psychological effects of LSD in a controlled study. Method A total of 20 healthy volunteers participated in this within-subjects study. Participants received LSD (75 µ g, intravenously) on one...

Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience

European Neuropsychopharmacology January 22, 2016 Thomas Pokorny, Katrin H. Preller, Rainer Kraehenmann et al. 148 citations

The mixed serotonin (5-HT) 1A/2A/2B/2C/6/7 receptor agonist psilocybin dose-dependently induces an altered state of consciousness (ASC) that is characterized by changes in sensory perception, mood, thought, and the sense of self. The psychological effects of psilocybin are primarily mediated by 5-HT2A receptor activation. However, accumulating evidence suggests that 5-HT1A or an interaction...

DOI: 10.1016/j.euroneuro.2016.01.005 (opens in new tab) Psilocybin Buspirone Hallucinogen 5-ht1 receptor +5

Classic hallucinogens in the treatment of addictions.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 4, 2016 Michael P. Bogenschutz, Matthew W Johnson

Addictive disorders are very common and have devastating individual and social consequences. Currently available treatment is moderately effective at best. After many years of neglect, there is renewed interest in potential clinical uses for classic hallucinogens in the treatment of addictions and other behavioral health conditions. In this paper we provide a comprehensive review of both...

The epistemic innocence of psychedelic states.

Consciousness and Cognition 2016 Chris Letheby 68 citations

One recent development in epistemology, the philosophical study of knowledge, is the notion of 'epistemic innocence' introduced by Bortolotti and colleagues. This concept expresses the idea that certain suboptimal cognitive processes may nonetheless have epistemic (knowledge-related) benefits. The idea that delusion or confabulation may have psychological benefits is familiar enough. What is...